China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 23 Apr, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- Tesla Becomes 1st Major Customer for Intel's 14A Chipmaking Process
- Trump Envoy Seeks to Replace Iran with Italy in World Cup
- Musk Warns of Likely SpaceX Chip Shortage, Aims to Make GPUs In-House
- South Korea's Q1 GDP Growth Roars Past Market on AI Chip Demand
- Xpeng to Begin Delivering Flying Cars in 2027
- TSMC Squeezes Smaller, Faster Chips from Old ASML Gear
- Jawbone Shaving and the Feminization of Korean Male Beauty Standards
- The Reality Behind the Asian Child Labor Scandals that Rocked Mega Brands
- Song: Thumb of Thunder
- SK Hynix to Invest $13 Billion in South Korea Plant to Meet AI Memory Demand